Abstract
As dendritic cells increasingly become the adjuvant of choice in new approaches to cancer immunotherapy, a degree of protocol standardization is required to aid future large-scale clinical trials.
MeSH terms
-
Cancer Vaccines / administration & dosage
-
Cancer Vaccines / adverse effects
-
Cancer Vaccines / therapeutic use*
-
Cell Differentiation
-
Dendritic Cells / cytology*
-
Dendritic Cells / immunology
-
Humans
-
Neoplasms / therapy
-
Quality Control